Vaughan David Investments’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$340K Sell
14,110
-198
-1% -$5.18K 0.01% 202
2026
Q1
$402K Buy
14,308
+1,866
+15% +$49.7K 0.01% 183
2025
Q4
$310K Buy
12,442
+25
+0.2% +$630 0.01% 197
2025
Q3
$316K Sell
12,417
-1,846
-13% -$45.6K 0.01% 192
2025
Q2
$346K Buy
14,263
+1,446
+11% +$33.7K 0.01% 182
2025
Q1
$325K Buy
12,817
+103
+0.8% +$2.69K 0.01% 176
2024
Q4
$337K Buy
12,714
+221
+2% +$6K 0.01% 177
2024
Q3
$362K Sell
12,493
-888
-7% -$25.9K 0.01% 171
2024
Q2
$374K Sell
13,381
-699
-5% -$19.2K 0.01% 165
2024
Q1
$391K Sell
14,080
-475
-3% -$13.2K 0.01% 172
2023
Q4
$419K Sell
14,555
-7,127
-33% -$215K 0.01% 157
2023
Q3
$719K Sell
21,682
-1,091
-5% -$38.6K 0.02% 130
2023
Q2
$835K Sell
22,773
-815
-3% -$31.7K 0.02% 131
2023
Q1
$962K Sell
23,588
-1,759
-7% -$76K 0.03% 126
2022
Q4
$1.3M Buy
25,347
+299
+1% +$14.3K 0.04% 118
2022
Q3
$1.1M Sell
25,048
-213
-0.8% -$10.3K 0.04% 120
2022
Q2
$1.32M Sell
25,261
-301
-1% -$15.3K 0.04% 117
2022
Q1
$1.32M Sell
25,562
-5,067
-17% -$263K 0.04% 118
2021
Q4
$1.81M Buy
30,629
+4,596
+18% +$228K 0.05% 112
2021
Q3
$1.12M Sell
26,033
-3,295
-11% -$146K 0.04% 117
2021
Q2
$1.15M Sell
29,328
-7,158
-20% -$278K 0.04% 121
2021
Q1
$1.32M Sell
36,486
-32,030
-47% -$1.14M 0.04% 112
2020
Q4
$2.52M Sell
68,516
-16,197
-19% -$594K 0.09% 96
2020
Q3
$2.95M Sell
84,713
-9,477
-10% -$332K 0.11% 92
2020
Q2
$2.92M Sell
94,190
-16,175
-15% -$550K 0.12% 88
2020
Q1
$3.42M Sell
110,365
-644,884
-85% -$22M 0.16% 89
2019
Q4
$28.1M Sell
755,249
-8,356
-1% -$298K 1.03% 38
2019
Q3
$26M Buy
763,605
+1,899
+0.2% +$69.1K 1% 46
2019
Q2
$31.3M Sell
761,706
-3,540
-0.5% -$141K 1.24% 20
2019
Q1
$30.8M Buy
765,246
+849
+0.1% +$34K 1.3% 20
2018
Q4
$31.7M Sell
764,397
-49,969
-6% -$2.07M 1.48% 15
2018
Q3
$34M Sell
814,366
-19,265
-2% -$742K 1.44% 15
2018
Q2
$28.7M Buy
833,631
+6,920
+0.8% +$236K 1.33% 18
2018
Q1
$27.8M Buy
826,711
+10,152
+1% +$349K 1.32% 22
2017
Q4
$28.1M Buy
816,559
+19,867
+2% +$677K 1.3% 22
2017
Q3
$27M Sell
796,692
-5,318
-0.7% -$171K 1.33% 19
2017
Q2
$25.6M Buy
802,010
+15,240
+2% +$481K 1.29% 22
2017
Q1
$25.5M Buy
786,770
+14,437
+2% +$455K 1.32% 20
2016
Q4
$23.8M Buy
772,333
+5,897
+0.8% +$180K 1.27% 26
2016
Q3
$24.6M Sell
766,436
-25,051
-3% -$838K 1.34% 20
2016
Q2
$26.4M Buy
791,487
+3,276
+0.4% +$105K 1.46% 12
2016
Q1
$22.2M Buy
788,211
+7,964
+1% +$227K 1.26% 31
2015
Q4
$23.9M Sell
780,247
-1,256
-0.2% -$39.5K 1.44% 15
2015
Q3
$23.3M Sell
781,503
-25,586
-3% -$820K 1.47% 12
2015
Q2
$25.7M Buy
807,089
+639
+0.1% +$20.8K 1.52% 13
2015
Q1
$26.6M Sell
806,450
-24,585
-3% -$782K 1.58% 10
2014
Q4
$24.6M Sell
831,035
-17,900
-2% -$513K 1.42% 15
2014
Q3
$23.8M Buy
848,935
+7,442
+0.9% +$209K 1.45% 14
2014
Q2
$23.7M Sell
841,493
-454
-0.1% -$12.9K 1.42% 18
2014
Q1
$25.7M Buy
841,947
+2,725
+0.3% +$81.2K 1.6% 9
2013
Q4
$24.4M Sell
839,222
-1,078
-0.1% -$31.4K 1.57% 14
2013
Q3
$22.9M Sell
840,300
-34,748
-4% -$945K 1.59% 10
2013
Q2
$23.3M Buy
+875,048
New +$24.2M 1.64% 10

Other funds holding PFE

Vaughan David Investments's PFE Position: Q2 2026 in Review

Vaughan David Investments reduced its Pfizer (PFE) stake by 1.4% in Q2 2026, selling an estimated $5.18K and leaving 14,110 shares worth $340K. The position accounts for 0.01% of the portfolio, ranked #202.

Vaughan David Investments first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $34M in Q3 2018. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Vaughan David Investments held 14,110 shares of Pfizer worth $340K as of Q2 2026.
  • Vaughan David Investments sold 198 Pfizer shares in Q2 2026, an estimated $5.18K.
  • Pfizer made up 0.01% of Vaughan David Investments's portfolio in Q2 2026, its #202 holding.
  • Vaughan David Investments first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Vaughan David Investments's Pfizer position peaked at $34M in Q3 2018.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Vaughan David Investments's 13F filing for Q2 2026, filed 11 Aug 2026.